Disease Mongering in Neurological Disorders
DOI:
https://doi.org/10.31053/1853.0605.v70.n4.7392Resumen
If out of curiosity, the readers take a few seconds to search on the Internet the expression “diseases mongering”, they will see that "to promote or sell disease" is an enforced definition. They will also find out that the term competes in popularity with many frequently used words, even with popular actors or sportsmen. Besides it will appear a number of “new diseases" or novel groupings or categories of “old diseases”. The main and common characteristic of all these "diseases" is that they are amenable to be treated with drugs. The first reason seems to be the advances in scientific knowledge. However, we should incorporate other considerations such as the interest of the pharmaceutical industry in selling their products...Descargas
Referencias
1-Payer, Lynn “Disease-Mongers: How Doctors, Drug Companies, and Insurers are Making You Feel Sick” Wiley, USA, 1994.
2- Andresik D., " Disease Mongering: El arte de fabricar enfermedades”, Biophronesis, Revista de Bioética y Socioantropologia en Medicina, 2009, nº.2, v.4"
3- Jairaj Kumar C., Abhizith D., Ashwini K., Arunachalam K., Hegde B. M., “Awareness and Attitudes about Disease Mongering among Medical and Pharmaceutical Students”, April 2006 , Volume 3 , Issue 4 ,e210, PLoS Medicine, published by the US Public Library of Science (PLoS).
4- Rose G (1985) Sick individuals and sick populations. Int J Epidemiol 14: 32–38.
5- Moynihan R. Cassels A. Selling sickness, Vancouver: Greystone Books, 2005. ISBN 1553651316
6- Cuestas E. The new strategies for disease mongering; Rev Fac Cien Med Univ Nac Cordoba.
2011;68(3):89-93.
7- Gilbert D, Walley T, New B. Lifestyle medicines. BMJ. 2000; 321:1341
8- Nasrallah HA, Loney J, Olson SC, McCalley- Whitters M, Kramer J, et al. (1986) Cortical atrophy in young adults with a history of hyperactivity in childhood. Psychiatry Res 17: 241–246
9- Swanson J, Castellanos FX (1998) Biological bases of attention deficit hyperactivity disorder. Program and Abstracts, NIH Consensus Development Conference on Attention Deficit Hyperactivity Disorder; 16–18 November 1998; Bethesda, Maryland. pp. 37–42.
10- Baughman FA (1999) ADHD—Total, 100% fraud [video]. Produced from the official video of the NIH Consensus Development Conference on Attention Deficit Hyperactivity Disorder; 16–18 November 1998; Bethesda, Maryland.
11- Sixto ME., Martínez González C., Quintana Gómez JL., “Disease mongering, el lucrativo negocio de la promoción de enfermedades”. Rev Pediatr Aten Primaria. 2009;11:491-512
12- Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.
13- Barry CL, Martin A, Busch SH. ADHD medication use following FDA risk warnings. J Ment Health Policy Econ. 2012 Sep;15(3):119-25.
14- Batstra L, Frances A. DSM-5 further inflates attention deficit hyperactivity disorder. J Nerv Ment Dis. 2012 Jun;200(6):486-8.
15- Holgate ST, Komaroff AL, Mangan D, Wessely S. Chronic fatigue syndrome: understanding a complex illness. Nat Rev Neurosci. 2011 Jul 27;12(9):539-44.
16- Richard M. Dasheiff, Editorial Neurology, Modafinil is not the new caffeine Richard M. Dasheiff. Neurology 2010;75:1764–1765
17- Kaiser PR, Valko PO, Werth E, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology 2010;75:1780 –1785.
18- Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J. The prevalence and cost of unapproved uses of top-selling orphan drugs. PLoS One. 2012;7(2):e31894
19- The NICE guideline on supporting people with dementia and their carers in health and social care this clinical guideline has been amended to incorporate the updated nice technology appraisal of drugs for alzheimer’s disease, published in march 2011 (www.nice.org.uk/guidance/ta217).
20- Gauthier S., Touchon J., “Mild cognitive impairment is not a clinical entity and should not be treated”. Arch Neurol 62: 1164–1166. 2005
21- Raschetti R., Albanese E., Vanacore N., Maggini M., “Cholinesterase inhibitors in mild cognitive impairment: A systematic review of randomised trials”. PLoS Med 4(11): e338. doi:10.1371/journal. pmed.0040338. 2007
22- Raftery James. Multiple Sclerosis risk sharing scheme: a costly failure. BMJ 2010; 340:c1672
23- NICE. Multiple Sclerosis-beta interferon and glatiramer acetate. Technology appraisal 32.2002
24- G Rice, B Incorvaia, L Munari, G Ebers, et al. Interferon in relapsing-remitting multiple sclerosis. Editorial Group: Cochrane Multiple Sclerosis Group. Published Online: 21 JAN 2009, The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
25- Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, Holloway RG, Dick AW. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology. 2011 Jul 26;77(4):355-63.
26- La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S, Filippini G.J Interferon β for secondary progressive multiple sclerosis: a systematic review. Neurol Neurosurg Psychiatry. 2012 Sep 5. [Epub ahead of print]
27- De Robles P., Recchia L., Gonorasky S. , Gonzalez Aguilar P. El costo derivado del número necesario a tratar. Revista Neurológica Argentina 2006; 31: 59-64
28- A Pratt, E Getzoff, J Perry, Amyotrophic lateral sclerosis: update and new developments. Degener Neurol Neuromuscul Dis. 2012 February; 2012(2): 1–14.
29- Ludolph A. and Jesse S. “Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials” Ther Adv Neurol Disord (2009) 2(5) 319–326
30- Guidance on the Use of Riluzole (Rilutek) for the Treatment of Motor Neurone Disease Published by the National Institute for Clinical Excellence January 2001
31- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev. 2012
32- Shorvon SD. Epilepsia. 1996;37 Suppl 2:S1-S3. Review.
33- Kwan P., Arzimanoglou A., Berg A., Brodie M., Hauser W., Mathern G., Moshé S., Perucca E. , Wiebe S., French J.; “Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies” ; Epilepsia Volume 51, Issue 6, pages 1069–1077, June 2010
34- B Westover, J Cormier, M Bianchi, M Shafi, R Kilbride, A Cole, S Cash. Revising the ‘‘Rule of Three ’’ for inferring seizure freedom ; Epilepsia, 53(2):368–376, 2012
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2013 Universidad Nacional de Córdoba
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Se permite la generación de obras derivadas siempre que no se haga con fines comerciales. Tampoco se puede utilizar la obra original con fines comerciales.
Cómo citar
